Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
India Globalization Capital, Inc is a conglomerates business based in the US. India Globalization Capital shares (IGC) are listed on the NYSE MKT and all prices are listed in US Dollars. India Globalization Capital employs 50 staff and has a trailing 12-month revenue of around USD$846,000.
|52-week range||USD$0.263 - USD$3.7|
|50-day moving average||USD$1.8609|
|200-day moving average||USD$1.5354|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.132|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$115,000|
|Return on assets TTM||-17.66%|
|Return on equity TTM||-35.18%|
|Market capitalisation||USD$88.5 million|
TTM: trailing 12 months
There are currently 2.4 million India Globalization Capital shares held short by investors – that's known as India Globalization Capital's "short interest". This figure is 41.8% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting India Globalization Capital shares can be evaluated.
India Globalization Capital's "short interest ratio" (SIR) is the quantity of India Globalization Capital shares currently shorted divided by the average quantity of India Globalization Capital shares traded daily (recently around 9.6 million). India Globalization Capital's SIR currently stands at 0.25. In other words for every 100,000 India Globalization Capital shares traded daily on the market, roughly 250 shares are currently held short.
However India Globalization Capital's short interest can also be evaluated against the total number of India Globalization Capital shares, or, against the total number of tradable India Globalization Capital shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case India Globalization Capital's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 India Globalization Capital shares in existence, roughly 50 shares are currently held short) or 0.0613% of the tradable shares (for every 100,000 tradable India Globalization Capital shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against India Globalization Capital.
Find out more about how you can short India Globalization Capital stock.
We're not expecting India Globalization Capital to pay a dividend over the next 12 months.
India Globalization Capital's shares were split on a 1:10 basis on 19 April 2013. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your India Globalization Capital shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for India Globalization Capital shares which in turn could have impacted India Globalization Capital's share price.
Over the last 12 months, India Globalization Capital's shares have ranged in value from as little as $0.263 up to $3.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while India Globalization Capital's is 5.1435. This would suggest that India Globalization Capital's shares are significantly more volatile than the average for this exchange and represent a higher risk.
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. The company operates through two segments, Infrastructure Business, and Life Sciences. It buys and sells infrastructure commodities, such as steel, wooden doors, marble, and tiles; rents heavy construction equipment, including motor grader, transit mixers and rollers; and undertakes highway construction contracts. The company also develops cannabinoid-based products and therapies, such as Hyalolex for the treatment of patients from anxiety, agitation, dementia, depression, and sleep disorder diseases; and Serosapse for the treatment of Parkinson's disease. In addition, it offers offer extraction, distillation, tolling, and white labeling services under the Holi Hemp brand; and hemp crude extracts, hemp isolates, and hemp distillates. The company operates in the United States, India, and Hong Kong. India Globalization Capital, Inc. was founded in 2005 and is based in Potomac, Maryland.
Everything we know about the Achilles Therapeutics plc IPO, plus information on how to buy in.
Everything we know about the SEMrush Holdings Inc IPO, plus information on how to buy in.
Everything we know about the ChargePoint IPO, plus information on how to buy in.
Everything we know about the Kaltura Inc IPO, plus information on how to buy in.
Everything we know about the Rocket Lab IPO, plus information on how to buy in.
Everything we know about the Soho House IPO, plus information on how to buy in.
Everything we know about the VIZIO IPO, plus information on how to buy in.
Everything we know about the IDW Media Holdings Inc IPO, plus information on how to buy in.
Everything we know about the Karooooo Ltd IPO, plus information on how to buy in.
Everything we know about the Connect Biopharma Holdings Limited IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.